Mirum Pharmaceuticals Inc (MIRM): יחס מחיר לרווח לקצב צמיחה

Risks of clinical trial failures for new indications create volatility, which is reflected in the P/E ratio and the growth rates of Mirum Pharmaceuticals. However, first-mover status in the therapy of pediatric cholestasis and patent protection strengthen the position of Mirum Pharmaceuticals. High pricing power in the orphan segment guarantees stable income. The value of 0.00 determines the current status of the parameter, highlighting the potential undervaluation of the asset.

The PEG ratio compares the current P/E multiple with earnings growth rates, allowing for the determination of an asset's fair value based on its dynamics. By analyzing the history of the P/E-to-growth ratio, an investor can identify the undervaluation of Mirum Pharmaceuticals (MIRM), whose market value should be supported by patent-protected drugs for the treatment of rare liver pathologies and stable production in the US.